NIAID

The National Institute of Allergy and Infectious Diseases (NIAID) is one of the 27 institutes and centres within the US National Institutes of Health (NIH), the world's largest funder of biomedical research. NIAID is the principal US federal agency for research on infectious and immune-mediated diseases, with a budget of approximately $6.3 billion annually (FY2025). Its mandate covers basic and clinical research on bacteria, viruses, parasites, and fungi with public health or pandemic relevance, as well as immune dysfunction conditions including HIV/AIDS, allergies, and autoimmune diseases. NIAID operates its own intramural laboratories and funds extramural research at universities and hospitals globally. The current director is Jeanne Marrazzo, appointed in 2023; Anthony Fauci served as director from 1984 to 2022.

NIAID researchers Flagg and Winski authored the May 2026 CDC Emerging Infectious Diseases study (DOI: 10.3201/eid3205.260053) demonstrating that the B3.13 H5N1 genotype replicates more efficiently in human nasal epithelium cultures than historical H5N1 strains and suppresses interferon-stimulated gene (ISG) responses, enabling partial evasion of innate immune defence. This is the most significant H5N1 pandemic risk-posture finding since the US dairy cattle outbreak began in 2024. The same study found that 66% of exposed dairy farm workers carry pre-existing neutralising antibodies from pdm09 H1N1, which may explain why human cases have remained sporadic despite the B3.13 strain's improving nasal fitness. NIAID's Rocky Mountain Laboratories BSL-4 facility in Hamilton, Montana conducts high-containment influenza research directly relevant to the ongoing dairy-cattle surveillance picture. NIAID also co-funds the major US H5N1 defensive programmes and monitors novel outbreak threats including the Kerala Nipah case confirmed on 11 June 2026, which remained contained with no secondary infections after two weeks.